Ribozyme-mediated specific gene replacement of the α1-antitrypsin gene in human hepatoma cells

Journal of Hepatology

Volumn 31, Issue 1, 1999, Pages 53-60

  Ozaki, Iwata ^a   Zern, Mark A ^a   Liu, Shuling ^a   Wei, Dan Lan ^a   Pomerantz, Roger J ^a   Duan, Lingxun ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Gene therapy; Ribozyme; 1 AT deficiency

Indexed keywords

ALPHA 1 ANTITRYPSIN; MESSENGER RNA; MUTANT PROTEIN; RIBOZYME; VIRUS VECTOR;

ALPHA 1 ANTITRYPSIN DEFICIENCY; ARTICLE; CONTROLLED STUDY; GENE REPRESSION; GENE TARGETING; GENE THERAPY; GENETIC TRANSDUCTION; HEPATOMA CELL; HUMAN; HUMAN CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

EID: 0032992064     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80163-9     Document Type: Article

References (31)

1. Crystal RG. α1-Antitrypsin deficiency, emphysema, and liver disease: genetic basis and strategies for therapy. J Clin Invest. 85:1990;1343-1352.
2. Sifers RN, Finegold MJ, Woo SL. Molecular biology and genetics of α1-antitrypsin deficiency. Semin Liver Dis. 23:1992;301-310.
3. Erikson S, Carlson J, Valez R. Risk of cirrhosis and primary liver cancer in α1-antitrypsin deficiency. N Engl J Med. 314:1986;736-739.
4. Curiel DT, Holmes MD, Okayana H, Brantley ML, Vogelmeier C, Travis WD, et al. Molecular basis of the liver and lung disease associated with the α1-antitrypsin deficiency allele Mmalton. J Biol Chem. 264:1989;13938-13944.
5. Dycaico MJ, Grant SG, Felts K, Nichols WS, Geller SA, Hager JH, et al. Neonatal hepatitis induced by α1-antitrypsin: a transgenic mouse model. Science. 242:1988;1409-1412.
6. Roemer K, Friedmann T. Concepts and strategies for human gene therapy. Eur J Biochem. 208:1992;211-225.
7. Chang AGY, Wu GY. Gene therapy: applications to the treatment of gastrointestinal and liver diseases. Gastroenterology. 106:1994;1076-1084.
8. Savransky E, Hyteroglow P, Harpaz N, Thung SN, Johnson EM. Correcting the PiZ defect in the α1-antitrypsin gene of human cells by targeted homologous recombination. Lab Invest. 70:1994;676-683.
9. Cech TR, Bass BL. Biological catalysis by RNA. Ann Rev Biochem. 55:1986;599-629.
10. Symons RH. Small catalytic RNAs. Ann Rev Biochem. 61:1992;641-671.
11. Haseloff J, Gerlach WL. Simple RNA enzymes with new and highly specific endoribonulease activities. Nature. 334:1988;585-591.
12. Sarver N, Cantin EM, Chang PS, Zaia JA, Ladre PA, Stephens DA, et al. Ribozymes as potential anti-HIV-1 therapeutic agents. Science. 247:1990;1222-1225.
13. Yu M, Ojwang J, Yamada O, Hampel A, Rappaport J, Looney D, et al. Hairpin ribozyme inhibits expression of diverse strains of human immunodeficiency virus type 1. Proc Natl Acad Sci USA. 90:1993;6340-6344.
14. Scanlon KJ, Jiao L, Funato T, Wang W, Tone T, Rossi JJ, et al. Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc Natl Acad Sci USA. 88:1991;10591-10595.
15. Kobayashi H, Dorai J, Holland JF, Ohnuma T. Reversal of drug sensitivity in multidrug-resistant tumor cells by an MDR1(PGY1) ribozyme. Cancer Res. 54:1994;1271-1275.
16. Feng M, Cabrera G, Deshane J, Scanlon KJ, Curiel D. Neoplastic reversion accomplished by high efficiency adenoviral-mediated delivery of an anti-ras ribozyme. Cancer Res. 55:1995;2024-2028.
17. Shore SK, Nabissa PM, Reddy EP. Ribozyme-mediated cleavage of the BCRABL oncogene transcript: in vitro cleavage of RNA and in vivo loss of P210 ptotein-kinase activity. Oncogene. 8:1993;3183-3188.
18. Denman RB. Using RNAFOLD to predict the activity of small catalytic RNAs. Biotechniques. 15:1993;1090-1094.
19. Davis ES, Harpaz N, Johnson EM. Expression of PiM- and PiZ-mutated forms of human α1-antitrypsin gene in transfected monkey Cosl cells. J Biol Chem. 265:1990;22153-22158.
20. Scharfmann R, Axelrod JH, Verma IM. Long-term in vivo expression of retrovirus-mediated gene transfer in mouse fibroblast implants. Proc Natl Acad Sci USA. 88:1991;4626-4630.
21. Lee SW, Gallardo HF, Gilboa E, Smith C. Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev responsive element decoy consisting of 13-nucleotide minimal Rev-binding domain. J Virol. 68:1994;8254-8264.
22. Adeniyi-Jones S, Romeo PH, Zasloff G. Generation of long read-through transcripts in vivo and in vitro by deletion of 3′-termination and processing sequences in the human tRNAiMet gene. Nucl Acid Res. 12:1984;1101-1115.
23. Miller AD, Buttimore C. Redesign of retrovirus packaging cell-lines to avoid recombination leading to helper virus production. Mol Cell Biol. 6:1986;2895-2902.
24. Chomczynski P, Sacchi N. Single-step step method of RNA extraction by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:1987;156-159.
25. Frizell E, Liu SL, Abraham A, Ozaki I, Eghbali M, Sage EH, et al. Expression of SPARC in normal and fibrotic livers. Hepatology. 21:1995;847-854.
26. Yun-Tso J, Xiao-Hong S, Teh-Hui K, Reece KS, Kay W. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: Genomic complexity and molecular evolution of the gene. Nucl Acid Res. 13:1985;2485-2502.
27. Rossi JJ. Controlled, targeted, intracellular expression of ribozymes: progress and problems. Trends Biotechnol. 13:1995;301-306.
28. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell. 70:1992;523-526.
29. Kastan MB, Onyekuere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
30. Sullenger BA, Lee TC, Smith CA, Ungers GE, Gilboa E. Expression of chimeric tRNA-driven antisense transcripts renders NIH3T3 cells highly resistant to moloney murine leukemia virus replication. Mol Cell Biol. 10:1990;6512-6523.
31. Thompson JD, Ayers DF, Malmstrom TA, McKenzie TL, Ganousis L, Chourira BM, et al. Improved accumulation and activity of ribozymes expressed from a tRNA-based RNA polymerase III promoter. Nucl Acid Res. 23:1995;2259-2268.